Funding Round supports Lead Compound Development

Orphan disease drug developers Minoryx Therapeutics (Barcelona) has completed a Series B funding round of €21.3M, which will enable the company to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.
The funding round was led by Fund+, joined by SFPI, S.R.I.W and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity).
The lead compound is currently in a phase 2/3 clinical trial for male patients affected by adrenomyeloneuropathy (AMN) the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD) in Europe and the US, with results expected in 2020.

Pilippe Monteyne representing Fund+ and Gery Lefebvre representing S.R.I.W were also welcomed to Minoryx’s Board of Directors by Chairman Khalid Islam.“Minoryx Therapeutics is a very promising company, at the leading edge of innovation in the field of rare diseases of genetic origin with a high unmet medical need”, said Philippe Monteyne. “Its unique approach convinced us of the value of its activities in the development of therapies that have the potential to become a world standard in multiple Central Nervous System indications.”

“We look forward to the next stages of development of Minoryx’s programs, supported here by the financial investment of Belgian players like Fund+, SFPI, S.R.I.W. and Sambrinvest”, said Gery Lefebvre. “We are very pleased to reinforce the link between Spain and Belgium, in particular with the Walloon ecosystem of the Charleroi Brussels South Biopark.”